These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation. Athauda A; Fong C; Lau DK; Javle M; Abou-Alfa GK; Morizane C; Steward K; Chau I Cancer Treat Rev; 2020 Jun; 86():101998. PubMed ID: 32203843 [TBL] [Abstract][Full Text] [Related]
8. Advances in the systemic treatment of therapeutic approaches in biliary tract cancer. Mirallas O; López-Valbuena D; García-Illescas D; Fabregat-Franco C; Verdaguer H; Tabernero J; Macarulla T ESMO Open; 2022 Jun; 7(3):100503. PubMed ID: 35696747 [TBL] [Abstract][Full Text] [Related]
9. Current and emerging immunotherapeutic approaches for biliary tract cancers. Yuan ZG; Zeng TM; Tao CJ Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):440-449. PubMed ID: 36115807 [TBL] [Abstract][Full Text] [Related]
10. Emerging targeted therapies and strategies to overcome resistance in biliary tract cancers. Demir T; Moloney C; Mahalingam D Crit Rev Oncol Hematol; 2024 Jul; 199():104388. PubMed ID: 38754771 [TBL] [Abstract][Full Text] [Related]
11. Systemic treatment of advanced or recurrent biliary tract cancer. Zhang W; Zhou H; Wang Y; Zhang Z; Cao G; Song T; Zhang T; Li Q Biosci Trends; 2020 Nov; 14(5):328-341. PubMed ID: 32830166 [TBL] [Abstract][Full Text] [Related]
12. Optimum chemotherapy for the management of advanced biliary tract cancer. Ghosn M; Kourie HR; El Rassy E; Chebib R; El Karak F; Hanna C; Nasr D World J Gastroenterol; 2015 Apr; 21(14):4121-5. PubMed ID: 25892861 [TBL] [Abstract][Full Text] [Related]
13. The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer. Berchuck JE; Facchinetti F; DiToro DF; Baiev I; Majeed U; Reyes S; Chen C; Zhang K; Sharman R; Uson Junior PLS; Maurer J; Shroff RT; Pritchard CC; Wu MJ; Catenacci DVT; Javle M; Friboulet L; Hollebecque A; Bardeesy N; Zhu AX; Lennerz JK; Tan B; Borad M; Parikh AR; Kiedrowski LA; Kelley RK; Mody K; Juric D; Goyal L Ann Oncol; 2022 Dec; 33(12):1269-1283. PubMed ID: 36089135 [TBL] [Abstract][Full Text] [Related]
14. Molecular profiling of biliary tract cancer: a target rich disease. Jain A; Javle M J Gastrointest Oncol; 2016 Oct; 7(5):797-803. PubMed ID: 27747093 [TBL] [Abstract][Full Text] [Related]
15. First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: "And Yet It Moves!". Rizzo A; Brandi G Cancer Treat Res Commun; 2021; 27():100335. PubMed ID: 33592561 [TBL] [Abstract][Full Text] [Related]
16. Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers. Tan ES; Cao B; Kim J; Al-Toubah TE; Mehta R; Centeno BA; Kim RD Cancer; 2021 Apr; 127(8):1293-1300. PubMed ID: 33289918 [TBL] [Abstract][Full Text] [Related]
17. Immunotherapeutic Approaches to Biliary Cancer. Shah UA; Nandikolla AG; Rajdev L Curr Treat Options Oncol; 2017 Jul; 18(7):44. PubMed ID: 28660602 [TBL] [Abstract][Full Text] [Related]
18. Targetable Molecular Alterations in the Treatment of Biliary Tract Cancers: An Overview of the Available Treatments. Valery M; Vasseur D; Fachinetti F; Boilève A; Smolenschi C; Tarabay A; Antoun L; Perret A; Fuerea A; Pudlarz T; Boige V; Hollebecque A; Ducreux M Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760415 [TBL] [Abstract][Full Text] [Related]
19. Treating Biliary Tract Cancers: New Targets and Therapies. Ho J; Fiocco C; Spencer K Drugs; 2022 Nov; 82(17):1629-1647. PubMed ID: 36441502 [TBL] [Abstract][Full Text] [Related]
20. Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. Pignochino Y; Sarotto I; Peraldo-Neia C; Penachioni JY; Cavalloni G; Migliardi G; Casorzo L; Chiorino G; Risio M; Bardelli A; Aglietta M; Leone F BMC Cancer; 2010 Nov; 10():631. PubMed ID: 21087480 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]